(Haven't been able to read through all the thread, so apologies if any of this has been raised already.)
I'd rework (10) a little. A lot of medications used for sleep, pain, headache disorders are technically prescribed off-label - even if there is trial evidence for them it may not be the licenced indication. I understand why you've grouped the two together into a generic unevidenced recommendations section rather than splitting out one prohibiting psychobehavioural interventions and the other limiting the use of pharmaceuticals to the relief of specific symptoms such as headache, sleep disturbance or pain and to trials - but a complete prohibition of all off-label prescribing for all symptoms would be very limiting.
2-3 weeks isn't going to be seen as credible. For routine outpatient referrals I think the only patients who will reliably get these days that are those on urgent cancer referral pathways (the "two-week rule" cases).
Some kind of protocol around environmental modification & priority access to side rooms might be seen as more feasible than dedicated beds, although the latter are really needed.
"ME/CF" should be "ME/CFS".
Obviously the recommendations cut right across the current policy objective to farm everything out to "multidisciplinary teams" in "the community". Perhaps expand on the rationale for this - it may also be worth specifying roles for GPs & others.
From what I have been able to glean NHS commissioning now has a particular focus on outcome metrics, KPIs, PROMS etc. I think you might end up having to at least define some measurable outputs if the goal is to produce something that will survive contact with commissioners rather than just being dismissed as a piece of advocacy. I think it would be well worth trying to find someone with detailed experience of NHS commissioning processes to advise.
Thanks for doing this. It has been needed for a very long time. (I
suggested something similar last year!)